Altamira Therapeutics (CYTO) Registration Filing summary

Company overview and business model

• Preclinical-stage biopharmaceutical company focused on peptide-based nanoparticle technologies for RNA delivery to extrahepatic tissues, with proprietary OligoPhore™ and Semaphore™ platforms.

• Two flagship siRNA programs (AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis) are in preclinical development; platform also supports mRNA and other RNA modalities for out-licensing.

• Recent strategic repositioning includes spinning off a majority stake in Altamira Medica AG (Bentrio® nasal spray) and plans to divest or partner additional clinical programs.

• Collaboration agreements and recent patent filings support ongoing development and expansion of the RNA delivery platform.

Financial performance and metrics

• Reports under IFRS; as of December 31, 2023, net tangible book value was $0.1 million ($0.05 per share), increasing to $2.7 million ($1.00 per share) pro forma for recent share issuances.

• Cash and cash equivalents as of December 31, 2023, were CHF 617,000; recurring losses and negative cash flows from operations since inception.

• Total cash need for 2024 estimated at CHF 5.0–6.0 million, prior to any offering proceeds.

• Substantial doubt exists about the ability to continue as a going concern; future funding requirements depend on development progress and external financing.

Use of proceeds and capital allocation

• Net proceeds from the offering are intended for working capital and general corporate purposes.

• Management has broad discretion over the use of funds; proceeds may be invested in short-term, investment-grade instruments pending use.